Emphysema - Pipeline Review, H2 2016

  • ID: 3946418
  • Report
  • 48 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Angion Biomedica Corp.
  • rEVO Biologics, Inc.
  • SATT North SAS
  • TGV-Laboratories
  • MORE
Emphysema - Pipeline Review, H2 2016

Summary

Our latest Pharmaceutical and Healthcare disease pipeline guide Emphysema - Pipeline Review, H2 2016, provides an overview of the Emphysema (Respiratory) pipeline landscape.

Emphysema is a type of COPD involving damage to the alveoli in the lungs. Symptoms include shortness of breath and cough with sputum. Risk factors include age, smoking, exposure to air pollutions, factory fumes, coal and silica dust. Treatment includes bronchodilators, antibiotics and steroids.

Report Highlights

Our Pharmaceutical and Healthcare latest pipeline guide Emphysema - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Emphysema (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Emphysema (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Emphysema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 8 and 1 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively for Emphysema.

Emphysema (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Emphysema (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Emphysema (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Emphysema (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Emphysema (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Emphysema (Respiratory)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Emphysema (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Emphysema (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Angion Biomedica Corp.
  • rEVO Biologics, Inc.
  • SATT North SAS
  • TGV-Laboratories
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Emphysema Overview

Therapeutics Development

Pipeline Products for Emphysema - Overview

Pipeline Products for Emphysema - Comparative Analysis

Emphysema - Therapeutics under Development by Companies

Emphysema - Therapeutics under Investigation by Universities/Institutes

Emphysema - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Emphysema - Products under Development by Companies

Emphysema - Products under Investigation by Universities/Institutes

Emphysema - Companies Involved in Therapeutics Development

Angion Biomedica Corp.

ProMetic Life Sciences Inc.

rEVO Biologics, Inc.

SATT North SAS

TGV-Laboratories

Emphysema - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

alpha-1 proteinase inhibitor (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alpha-1 proteinase inhibitor (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody for Emphysema - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BB-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EDO-66 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MG-53 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit EMAP II for Emphysema - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mul-1867 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Inhibit Beta Galactosidase for Pulmonary Emphysema - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Human Alpha-1 Antitrypsin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TM-5441 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Emphysema - Dormant Projects

Emphysema - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Emphysema, H2 2016

Number of Products under Development for Emphysema - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Emphysema - Pipeline by Abeona Therapeutics, Inc. , H2 2016

Emphysema - Pipeline by Angion Biomedica Corp., H2 2016

Emphysema - Pipeline by ProMetic Life Sciences Inc., H2 2016

Emphysema - Pipeline by rEVO Biologics, Inc., H2 2016

Emphysema - Pipeline by SATT North SAS, H2 2016

Emphysema - Pipeline by TGV-Laboratories, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Emphysema - Dormant Projects, H2 2016

Emphysema - Discontinued Products, H2 2016

List of Figures

Number of Products under Development for Emphysema, H2 2016

Number of Products under Development for Emphysema - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Angion Biomedica Corp.
ProMetic Life Sciences Inc.
rEVO Biologics, Inc.
SATT North SAS
TGV-Laboratories
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll